Riata TM Publications
|
|
- Branden Watson
- 5 years ago
- Views:
Transcription
1 St. Jude Medical Implantable Electronic Systems Valley View Court Sylmar, CA USA Main Fax Riata TM Publications Citation Mean follow-up Data From Results Lorvidhaya P et al. "Prospective evaluation of cinefluoroscopy and chest radiography for Riata lead defects: Implications for future lead screening." Journal of Interventional Cardiac Electrophysiology :2 ( ). time from implant: 6.8±2.2 yrs for abnormal Riata, 6.2±2.2 for normal Riata Cardiac Arrhythmia Service, Warren Alpert Medical School of Brown University Cinefluoroscopy of 102 Riata lead patients showed externalized conductors in 33 patients (32 %). Twenty-five of 33 patients (76 %) who had abnormal cinefluoroscopic findings had abnormal CXR findings on blinded review. Liu J et al. Longitudinal Follow-Up of Externalized Riata Leads. The American Journal of Cardiology, Volume 112, Issue 10, 15 November 2013, Pages ±2.9 UPMC: n=329 Riata leads fluoroed Externalization was present in 76 patients (23%); of whom, 24 (32%) had the Riata lead replaced shortly after screening. The remaining 52 patients were followed for 7.9 ± 2.9. Prospective follow-up data on externalized Riata leads suggest an electrical failure rate in excess of 6% per year. Marcus G et al. "The year in review of clinical cardiac electrophysiology." Journal of the American College of Cardiology 24 December (25): N/A Review paper about studies from April 2012 through May 2013 Summarizes results from the VA, Abdelhadi, and Canadian HRS studies. Chuen M et al. "Single centre experience of implanted Riata and Riata ST Silicone coated leads at the Liverpool Heart and Chest Hospital." Europace (2013) 15 (suppl 4): iv4- iv8. doi: /europace/eut314 Steinberg C et al. "High annual incidence of new riata insulation defects in a prospective cohort." Canadian Journal of Cardiology :10 SUPPL. 1 (S193). 6.4 ± 1.2 Liverpool Heart and Chest Hospital (n=38) At a mean of 5.7±2.7 following implant, 21% of patients had externalized conductors and 10.8% had lead fractures. All leads with poor performance were 8Fr leads. Lead fractures occurred earlier and in younger patients than those w/ EC. 12 Quebec Sixty-nine patients (24.3%) had conductor externalization. The mortality rate at 12 showed no difference between visually abnormal and normal Riata leads (8.1% vs 8.8%, p=0.82). Significantly more patients with abnormal leads underwent lead revision (21.3% vs 3.4%, p<0.001). The overall incidence of new radiologic insulation defects was 12.1% (11/91 leads) over a period of one year follow-up. New lead breaches were most frequent in the 1590 lead model (21.4%) and in the 1580 model (12.2%). There were no further differences in electrical abnormalities between normal and abnormal Riata leads over the follow-up period.
2 Steinberg C et al. "Pa/lateral chest X-ray is non-inferior to fluoroscopy for the detection of insulation defects in riata defibrillation leads." Canadian Journal of Cardiology :10 SUPPL. 1 (S360). Steinberg C et al. "High voltage testing of riata defibrillation leads with insulation defects-a single center experience." Canadian Journal of Cardiology :10 SUPPL. 1 (S359- S360) Richardson T et al. "Comparative outcomes of transvenous extraction of sprint fidelis and riata defibrillator leads: a single center experience." Journal Of Cardiovascular Electrophysiology [J Cardiovasc Electrophysiol] 2014 Jan; Vol. 25 (1), pp Date of Electronic Publication: 2013 Sep 12. Segreti L et al. "Transvenous removal of recalled ICD leads: Riata vs. Sprint Fidelis." Eur Heart J (2013) 34 (suppl 1): doi: /eurheartj/eht309.P3654 Mahajan D et al. "Different manifestations of right ventricular ICD advisory leads using impedance and noise." Eur Heart J (2013) 34 (suppl 1): doi: /eurheartj/eht308.P1393 N/A Quebec The odds ratio to detect insulation defects on CXR was (95%CI ), which was significant for non-inferiority (p=0.026). The sensitivity of a PA/Lateral CXR was 97.3%, the specificity 88.9% and the test accuracy 93.2%. The total radiation dose of a PA/Lateral CXR was 0.09mSv compared to 0.23mSv with fluoroscopy. CXR was significantly less time-consuming and also less expensive than fluoroscopy. N/A Quebec (45 pts) Thirty-five patients with abnormal leads were compared to a control group of 10 patients with normal leads. Loss of lead integrity was observed in 2 abnormal leads after shock delivery. In one patient there was an undetectable HV-impedance post shock and the other showed an HVimpedance >200Ω. In the other patients, the pre- and post-shock HV-impedance showed no difference between abnormal and normal leads (53±12Ω vs 47±7Ωp=0.08). N/A Mean pacing period was 39.1±22.1 in conductor fracture group and 36.1±23.4 in externalized conductors group. Vanderbilt University Hospital University Hospital of Pisa, Pisa Italy There were significant differences between those undergoing extraction of a Sprint Fidelis (n=145) or Riata lead (n=47). In the Riata group, device-related endocarditis was a more common indication for extraction, the mean duration of implant was longer, and larger excimer laser sheaths were required. Lead malfunction was a more common indication in the Fidelis group. Extraction success in 93/94 (98.9%) with externalized conductor leads. No major complications occurred. N/A Boston Scientific 995 randomly selected pts with advisory leads were followed via remote monitoring system, and an automatic algorithm classified tachy episodes and impedance data from 579 Fidelis and 416 Riata leads. Most episodes were classified as Noise, not EMI by the experts. 24 Fidelis and 10 Riata patients had RV impedance 2000.
3 Kouraki K et al. "Incidence of Riata lead failure in clinical practice: a single center experience." Eur Heart J (2013) 34 (suppl 1): doi: /eurheartj/eht308.P1405 Badenco N et al. "Riata and Riata ST defibrillator leads failure: cable externalization is one problem, but other electrical failures seem more preoccupant". Eur Heart J (2013) 34 (suppl 1): doi: /eurheartj/eht308.P1396 Fischer A et al. Contribution of ethylenetetrafluoroethylene (ETFE) insulation to the electrical performance of Riata silicone leads having externalized conductors. J Interv Card Electrophysiol Aug;37(2): Available at: doi: /s x. Epub 2013 Mar 26. Kubala M et al. Progressive decrease in amplitude of intracardiac ventricular electrogram and higher left ventricular ejection fraction are associated with conductors' externalization in Riata leads. Europace Aug;15(8): Available at: doi: /europace/eut015. Epub 2013 Feb 6. Liu J et al. Failure-free survival of the Durata defibrillator lead. Europace Jul;15(7): Available at: doi: /europace/eut010. Epub 2013 Feb 1. 3 Heart Center Ludwigshafen (Ludwigshafen am Rhein, Germany) 86 pts completed f/u of 74 N/A 2 AP-HP hospitals in France Bench testing: ETFEcoated conductors 57±30 Patients = 36. Leads: Riata 12 single-coil, 24 dual-coil (1570 N=4, 1580 N=12, 1582 N=7, 7000 N=7, 7002 N=6). Durata: 2.3±1.2. Riata: 3.2±2.1. Quattro: 3.5±2.7. Leads: Durata (n = 828), Riata [n = 627; 8 Fr. (n = 472) and 7 Fr. (n = 155)], or Sprint Quattro (n = 1020). During a follow-up time of three, 111 (16.3%) of the leads had to be replaced, 37 (5.4%) because of pacing/sensing problems and 74 (10.9%) because of lead failure. Overall failure rate was 32.5% (28 patients); all were observed in 8-French leads except for one patient. There were 10 pts with oversensing including 5 related to insulation damages and 5 without, none of them have shown cable externalization, 8 conductor fractures, 7 conductor externalizations without electrical abnormality, and 3 other isolated electrical problem such as impedance increase (11.6%, 9.3%, 8.1%, and 3.5% respectively). Mean time to failure was 62. Testing of ETFE-coated conductors following multiple preconditioning steps showed that ETFE serves as a redundant layer of insulation. In the event that the ETFE coating is breached, the potential gradient seen resulting from a highvoltage defibrillation shock was similar to a lead with no breach to the ETFE, even after 100 shocks. Externalized conductors were identified in 12 (33%) patients after a 53-month (13 114) mean delay. Detection of the conductors externalization was preceded by an electrical lead abnormality in 10 (83%) patients. Lead failure was defined as electrical malfunction resulting in lead replacement, excluding dislodgements or perforations. Annual electrical failure rates were 0.3%, 1.7, and 0.3% for the Durata, Riata, and Sprint Quattro leads, respectively (P < for the comparison of Durata to Riata and P = 0.01 for the comparison of Durata to Sprint Quattro). The failure-free survival of the Durata lead was significantly better than that of the Riata lead (P < ) and similar to that of the Sprint Quattro (P = 0.94). The 7 Fr. Riata ST lead had better survival compared with the 8 Fr. Riata lead (P = 0.050) and comparable survival with the Durata lead (P = 0.12).
4 Moorman LP et al. Increasing lead burden correlates with externalized cables during systematic fluoroscopic screening of Riata leads. J Interv Card Electrophysiol Jun;37(1):63-8. doi: /s Epub 2012 Dec 20. Brunner M et al. Transvenous extraction of implantable cardioverter defibrillator leads under advisory a comparison of Riata, Sprint Fidelis, and non-recalled implantable cardioverter defibrillator leads. Heart Rhythm Jun 28. pii: S (13) Available at: 1 Cheung J et al. Mechanisms, Predictors and Trends of Electrical Failure of Riata Leads. Heart Rhythm (Uncorrected Proof.) Available at: 5. Larsen J et al. Nationwide fluoroscopic screening of recalled Riata defibrillator leads in Denmark. Heart Rhythm Jun;10(6): Available at: 0. Lau E et al. Differential Lead Component Pulling as a Possible Mechanism of Inside-Out Abrasion and Conductor Cable Externalization. Pacing Clin Electrophysiol Jun 7. doi: /pace [Abstract] Lau EW. Compression-bending of multicomponent semi-rigid columns in response to axial loads and conjugate reciprocal extensionprediction of mechanical behaviours and implications for structural design. Journal of The Mechanical Behavior of Biomedical Materials. 2013;17: N/A Patients = 48 (Riata 8F N = 23, Riata 7F N = 25). N/A Median: 4.1 Extraction procedures. Leads (N=2,056): ICD leads = 1,215 with 122 Riata, 309 Sprint Fidelis. Leads: Riata/ST (N=316) 1 (0.3%) model 1570, 160 (51%) model 1580, 15 (4.7%) model 1581, 76 (24%) model 1582, 2 (0.6%) model 1590, 50 (16%) model 7000, 2 (0.6%) model 7001, 10 (3%) model Center = ± 1.1 Patients = 299 with recalled Riata leads. Externalized cables were seen in ten patients (21 %). Another five patients (10 %) were determined to have abnormal cable spacing, likely denoting early or partial erosion. The remaining 33 (69 %) had normal fluoroscopic appearance. Procedural outcomes for Riata and Sprint Fidelis TLEs (transvenous lead extractions) were no different.. Rates of clinical success, failure, and major complications were no different in the recalled and nonrecalled ICD lead TLE procedures. During median follow-up of 4.1, the Riata lead electrical failure rate was 6.6%. The rate of externalized conductors among failed leads was 57%. Engineering analysis of 10 explanted leads revealed 5 (50%) leads with electrical failure due to breach of ethylene-tetrafluoroethylene (ETFE) conductor coating. The rate of Riata lead failure was initially noted to increase exponentially with a power of 2.1 but leads functioning past 4 had a linear pattern of failure with a power of 1.0. The prevalence of externalization was 32 of 298 (11%) at a mean dwell time of 5.1. The prevalence was 21 of 98 (21%) for 8-F leads and 11 of 200(6%) for 7-F leads. No association was observed between externalization and electrical function. Fluoroscopic diagnostic performance was good with positive and negative predictive values of 88% and 99%, respectively. N/A Bench testing Restitution from differential pulling followed three patterns: complete, partial without escalation, and incomplete with escalation. Only the last pattern (only shown by the Riata 8F and ST 7F leads) was associated with an increased risk to conductor cable externalization.
5 Hayes D et al. Prevalence of Externalized Conductors in Riata and Riata ST Silicone Leads: Results from the Prospective, Multicenter, Riata Lead Evaluation Study. Heart Rhythm, Available online 27 August Jayam V et al. Does the Riata Lead Deliver Adequate Defibrillation Shocks? A Single Center Experience in 289 Patients. Heart Rhythm The Riata Conundrum AB11-02 Goyal S et al. Lead Thrombi Associated with Externalized Cables on Riata ICD Leads: A Case Series. Journal of Cardiovascular Electrophysiology. doi: /jce Epub 2013 Apr 11. Greenslade J et al. Single centre experience with Riata defibrillator leads. Heart, Lung and Circulation. 2013;22: Available at: Kremers M et al. The National ICD Registry Report: Version 2.1 including leads and pediatrics for 2010 and Heart Rhythm. 2013; 10(4): e59-e65. Available at: 5. Patel D et al. Extraction of defibrillator leads recalled for cable externalization and failure. J Interv Card Electrophysiol Apr;36(3): doi: /s Epub 2012 Nov 21. Riata ST (7F): 4.8 ± 0.9 ; Riata (8F): 6.5 ± patients are included in the analysis: 517 with 8F leads, 259 with 7F leads patients; 266 leads were 8F, 21 leads were 7F Mean: 7.6 ± 1.5 Implanted between 2002 and Paper published in Therefore, follow-up = Implant to presentation with failure = 8 mo to 7 yrs. N/A Leads: Riata 1580 (N=4), Riata 1581 (N=1) Leads: Riata (N=100). The National ICD Registry. Leads: Riata 8-F (N=8755), Riata 7-F (N=3213), Fidelis (N=23234). Centers = N/A Patients = 627. Leads: Riata 1580, 1581, 1582, 1590 or Riata ST 7000 and Overall prevalence of externalized conductors in 7F leads is significantly lower than 8F leads (p < 0.001); For leads implanted 6, prevalence of EC was also significantly greater in 8F leads (18.8% or 32/170) compared with 7F leads (9.4% or 24/256, p=0.005); Overall there were 10 leads (1.3%, CI: %) with electrical dysfunction Externalized conductors was observed in 13.1% of 8F leads and 4.8% in 7F; failure of defibrillation efficacy only occurred in one patient; in 99% of this cohort, sensing and HV function remained intact. (Riata) leads should be screened for thrombi prior to potential lead extraction to determine the safest approach. Serial echocardiography may help detect progressive thrombus formation. The role of systemic anticoagulation for prevention or treatment of these thrombi remains unclear. Overall 9% of these Riata leads presented with indications of electrical failure. This resulted in three patients with failed therapy, and all nine required lead revision (N=5), 1571 (N=1), 1580 (N=1), 1581 (N=2). There were 8755 St Jude Medical Riata 8-F leads ( series model numbers) and 3213 Riata ST 7-F leads( series model numbers) identified. Of those functionally assessed, 715 (8.2%) 8-F leads and 236 (7.4%) 7-F leads functioned abnormally. These leads were extracted or abandoned in 929 (10.6%) and 345 (10.7%), respectively. 20 lead extraction cases. Reasons for extraction included electrical malfunction of the lead (n=8) such as increased pacing threshold or non-capture, electrical noise sensed on the lead, poor R wave sensing, or RV lead pacing or shocking impedance outside of the normal range, lead and device infection (n=5), and patient preference after becoming aware of the class I FDA recall (n=7).
6 Steinberg C et al. Detection of high incidence of Riata lead breaches by systematic posteroanterior and lateral chest X-ray in a large cohort. Europace2013;15(3): Mean time since implantation 6.7 for abnormal leads and 5.9 for others Patients = 284. Leads: Riata 1570, 1580, 1582, 1590, 1592, 7000, 7002, and The total frequency of radiological lead defects was 24.3%. Insulation breaches occurred at zones of major lead curvature. Abnormal CXRs were more frequent in 8F leads (31.4% vs. 6.3%; P, 0.001). Most defects occurred with lead models 1582 (41.2%) and 1580 (31.4%). Valk S et al. Long-term performance of the St Jude Riata ICD lead family. Neth Heart J Mar;21(3): Lindemann J et al. The Role of Lead Integrity Alerts and Remote Monitoring in Reducing Morbidity Associated With the St Jude Medical Riata ICD Lead. Heart, Lung and Circulation. 2013;22(1): S123. Available at: ( ) Median: 17 mo Patients = 374. Electrical abnormalities (mainly noise, 65 %) were observed in 20/257 patients (7.8 %). Definite conductor externalisation was confirmed with fluoroscopy or chest X-ray in 16 patients, and in one after extraction. Median time to conductor externalisation was 5 (IQR ). Lead externalisation was observed in 5.4 % (95 % CI ) at 5 and 22.7 % (95 % CI ) at 8. N = 103 normally functioning Riata leads. 39 on remote-monitoring. 61 with LIA enabled device. At a median follow up of 17, 8% (8/103) failed. The median time to failure was Fazal I et al. Comparison of Sprint Fidelis and Riata defibrillator lead failure rates. Int J Cardiol Nov 5. pii: S (12) Available at: doi: /j.ijcard [Epub ahead of print] Sprint Fidelis: 53.0±22.3 mo. Riata: 54.8±26.3 mo. Riata patients: 106. In the Riata lead group there were 13 lead failures (11.3%, 2.71% per year) over 54.8±26.3 follow-up with a mean time to failure of 53.5±24.5. Shen S et al. Prevalence and predictors of cable extrusion and loss of electrical integrity with the Riata defibrillator lead. J Cardiovasc Electrophysiol Nov;23: Available at: doi: /j x. Epub 2012 Jun 14. Mean: 67±25 mos Patients = /84 = Riata /84 patients (27.4%) had fluoroscopic evidence of cable extrusion. All 23 patients had normal electrical parameters on routine device interrogation. Fifteen of these 23 patients (65%) with extruded cables had high-voltage shocks within 12 of lead screening; only one patient demonstrated postshock electrical abnormalities. Sato A et al. Insulation Defects in Riata Implantable Cardioverter-defibrillator Leads. Intern Med. 2012;51(19): Epub 2012 Oct 1. Mean: 52 ± 9 Leads: Riata 1580 or 1581 (N = 10) The presence of externalized conductors was observed in 2/10 patients (20%).
7 Theuns D et al. Prevalence and presentation of externalized conductors and electrical abnormalities in Riata defibrillator leads after fluoroscopic screening: Report from the Netherlands Heart Rhythm Association device advisory committee. Circ Arrhythm Electrophysiol Dec;5: Steinberg C et al. High Prevalence of Riata Insulation Defects Detected by Systematic PA/Lateral Chest-X Ray - A Single Center Experience. Canadian Journal of Cardiology. 2012;28(5): S393-S394. Available at: Abraham P et al. High incidence of unexpected defibrillation coil retention during orthotopic heart transplantation. J Heart Lung Transp. 2012;31(8): Available at: 3. Median: Riata 71.7, Riata ST 51.1 Implanted Paper published in Therefore, follow-up = Mean: 36 ± 30 Leads: Riata (N = 484), Riata ST (N = 545) Centers = 31 N = 269 patients. Center = 1. Leads: 84 (Biotronik 12%, Boston Scientific 22%, Medtronic 30%; and St. Jude Medical 36%) Center = 1 The presence of externalized conductors was observed in 147/1029 patients (14.3%). A higher proportion of the 8-F Riata family had externalized conductors than the 7-F Riata ST family (21.4% vs. 8.0%; P < 0.001). Median time from implantation to detection of externalized conductors was The estimated rates of externalized conductors were 6.9% and 36.6% at 5 and 8 after implantation, respectively. Of the 147 leads with externalized conductors, 10.9% had abnormal electrical parameters vs 3.5% in nonexternalized leads (P<0.001). The overall prevalence of radiological insulation defects was 24.1%. Insulation breaches occurred at zones of major lead curvature. Most lead defects occurred in lead models 1582 (37.5%) and 1580 (31.8%). Abnormal CXR were more frequent with 8F leads (31.3 vs 6.5%; p<0.001) and with dual-coil leads (29.2% vs 14.4%; p=0.01). Abnormal leads had higher shocking lead impedances (69±14Ohm vs. 54±13Ohm; p=0.03) and higher capture thresholds (1.12±1.82V vs. 0.91±0.38V; p=0.01). Cable externalization was associated with significant lead dysfunction, mostly pathological pacing thresholds and sensing abnormalities. There was no difference in the incidence of inappropriate shocks. 7 out of 11 lead-related adverse events in orthotopic heart transplantations in the single center were associated with Riata With the usual cut, the defibrillation coil can easily stay in place, fibrously affixed to the vasculature. The authors suggest that the intersection of the ICD lead should not be done through the coil; instead, the lead should be cut through between the 2 coils. Liu J et al. Class I recall of defibrillator leads: a comparison of the Sprint Fidelis and Riata families. Heart Rhythm Aug;9(8): Epub 2012 Apr 3. Available at: 3. Riata: 3.2 ± 2.1 Fidelis: 2.7 ± 1.3 Quattro: 3.5 ± 2.7 Leads: Riata (N = 627), Sprint Fidelis (N = 623), Sprint Quattro (N = 1020). Riata (models 1580, 1581, 1582, and 1590; n = 472) or Riata ST (models 7000 and 7001; n = 155) The failure-free survival of the Sprint Quattro lead was significantly better than that of the Riata lead (P = ), which in turn was better than that of the Sprint Fidelis lead (P = ). Riata 8F silicone leads showed a significantly higher failure rate than Riata ST 7F silicone leads (p = ).
8 Liu J et al. Fluoroscopic screening of asymptomatic patients implanted with the recalled Riata lead family. Circ Arrhythm Electrophysiol Aug 1;5(4): doi: /CIRCEP Epub 2012 Jul 11. Ng J et al. St Jude Medical Riata High Voltage ICD Lead Long Term Performance Report a Single Centre Experience. Heart, Lung and Circulation. 2012;21(1): S138-S139. Available at: Parvathaneni S et al. Fluroscopic Grading Scale and Correlation to Lead Extraction in Failed SJM Riata Family ICD Leads. Heart Rhythm 2012;9(5):S13. AB06-03 Median: 5.6 Mean: 40 mo (0-86 mo) Mean: 5.67 Leads = 245, centers = 1 Leads: N = 171 Riata leads (49% 7000, 32% 1580, 11% 1581, 6% 7001 and the remainder; 1570, 1571 and 7040). Pt: N = 161. Leads screened = 52, centers = 1 53 of 245 leads (21.6%) exhibited externalized conductors (median implant time 5.6 ). Externalized conductor rates were similar in equal numbers of leads examined between time periods and > 6.2 after implant, suggesting a possible plateau in externalized conductors rates after 6.2 from implantation date. Riata 8F leads accounted for 87% of leads with externalized conductors. 17% (29/171) required intervention. Presenting problems (not mutually exclusive) were infection 2.5%, noise 5.0%, inappropriate shocks 6.2%, high thresholds and or small R wave 8.1%, sudden impedance change 3.1%, dislodgement 3.1%, t-wave over-sensing 0.6%, late perforation 0.6%. 34.6% (18/52) of Riata leads had externalized conductors. 22.2% (4/18) of these leads had significant lead or shock impedance changes. Parvathaneni SV, Ellis CR, and Rottman JN. High prevalence of insulation failure with externalized cables in St. Jude Medical Riata family ICD leads: fluoroscopic grading scale and correlation to extracted leads. Heart Rhythm. 2012;9(8): Sung R et al. Long-term electrical survival analysis of Riata and Riata ST silicone leads: National Veterans Affairs experience. Heart Rhythm Dec;9: Available at: doi: /j.hrthm Epub 2012 Aug 4. Sung RK, et al. Survival Analysis of St. Jude Medical Riata and Riata ST High-Voltage Leads in Comparison to Medtronic Sprint Quattro, Fidelis and Boston Scientific Endotak Leads. Heart Rhythm 2012;9(5):S13. Abstract AB06-01 Wright J et al. Varying Modes of Presentation of Lead Failure in the 8F Silicone Riata ICD Lead. Heart, Lung and Circulation. 2012;21(supp 1): S142. Available at: Mean: 5.9±3.45 Riata 15xx: 6.35±1.2. Riata 7xxx: 4.07±0.7. Up to 10 OR 60 survival Leads screened: Riata = 87. Centers = 1. Leads: 1,403 Riata + Riata ST, 6,091 Quattro, 5,072 Fidelis, 2,401 Endotak Reliance G/SG. Centers = VA NCDSC remote monirtoring Leads: 1,262 Riata + Riata ST, 5,608 Quattro, 5,076 Fidelis, 2,401 Endotak Reliance G/SG, centers = VA NCDSC remote monirtoring Median: 58 mo Lead: 432 Riata. Center = 1. Externalized cables was seen in 33.3% (29/87) of the patients. 31% (9/29) of the leads with exposed cables showed electrical failure, and 29.7% (19/64) of the leads with normal electrical data contained externalized cables. Time from implant 5 predicted structural lead failure (P < 0.05). X-ray grade compared with extracted leads demonstrated a sensitivity and specificity of 86% and 100% respectively. Riata/Riata ST lead survival at 5 was significantly higher than Fidelis (97.5% vs. 89.6%), but lower than Quattro (99.2%) and Endotak (99.5%). 60-month survival probability: Riata: 97.5%, Quattro: 99.2%, Endotak: 99.5%, Fidelis: 89.6%. Riata survival significantly higher than Fidelis, but lower than Quattro and Endotak. Lead failure resulted in 10% of Riata leads undergoing revision during long term follow-up. Noise and changes in impedance related to insulation failures being the most common abnormality.. DFT testing should be routinely performed at generator change to ensure normal function. Remote monitoring may be of
9 value to allow earlier detection of potential lead problems. Van Rees J et al. Update on small-diameter implantable cardioverter-defibrillator leads performance. Pacing Clin Electrophysiol Jun;35(6): doi: /j x. Epub 2012 Feb 21. Parkash R et al. Riata Leads Failure: Report from the CHRS Device Committee. Heart Rhythm 2012;9(5):S13. AB Parkash R, Exner D, Champagn J, et al. Failure rate of the Riata lead under advisory: A report from the CHRS Device Committee. Heart Rhythm. 2013;10(5): Available at: 8. Hauser R et al. Riata implantable cardioverter-defibrillator lead failure: analysis of explanted leads with a unique insulation defect. Heart Rhythm. 2012;9(5): Hauser R et al. Deaths Caused By the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads. Heart Rhythm Aug;9: Available at: 8. Epub 2012 Mar 23. Hauser R et al. Deaths caused by Riata ICD Lead failure: Analysis of the U.S. FDA Device Database. European Heart Journal SUPPL. 1 (540) Abstract Sprint Fidelis: 3.4±1.5 yr. Riata 8-F: 4.6±2.6 yr. Riata 7-F: 2.9±1.3 yr. Benchmark: 3.4±2.7 yr. Mean: 4.1 Mean: ± 18.6 Riata: 61 ± 21 Riata ST: 36 ± 7 Leads: Fidelis (N=396), Riata 8-F (N=165), Riata 7- F (N=30), benchmark cohort (N=1602). Riata leads (N = 4704): 60% Riata 8F, 40% Riata ST 7F, centers = 22 Riata leads (N = 4358, as of Mar 2012): Riata 8F 65.3%, Riata 7F 32.4%, unknown 2.3%. centers = 21 MAUDE Database (Sept 2011), SJM lead return analysis reports, leads = 105 with inside-out abrasion MAUDE Database The yearly lead failure rate of the Sprint Fidelis lead, 7-F Riata lead, 8-F Riata lead, and the benchmark cohort was 3.54%, 2.28%, 0.78%, and 1.14%, respectively. In comparison to the benchmark cohort, the adjusted hazard ratio of lead failure was 3.7 (95% confidence interval [CI] , P < 0.001) for the Sprint Fidelis lead and 4.2 (95% CI , P < 0.05) for the 7-F Riata lead. 7.1% of leads were replaced 3.7% for confirmed lead failure. There were 26% that underwent extraction, 16% by laser lead, the remainder by manual traction. Electrical abnormalities were reported in 4.6% of the affected leads; 8.0% of these were found to have concomitant radiographic evidence of externalization. The rate of electrical failure was higher in the 8-F (5.2%) vs7-f(3.3%) leads(p <.007). Among the leads that were replaced, 21% were extracted. Two major complications (1.0%) were attributed to extraction of these leads. A total of 226 insulation defects were found in 105 Riata and Riata ST leads. 32 leads were reported to show exposed cables or externalized conductors. Over 8, 133 deaths associated with Riata leads were identified in the MAUDE database: 71 involving Riata silicone and Riata ST silicone leads and 62 involving Quattro Secure leads. 20% of deaths (27/133) were lead-related. Of these, 22 were caused by Riata or Riata ST lead failure and 5 were caused by Quattro Secure lead failure. Riata/ST lead failure deaths were typically caused by short circuits between high-voltage components. No death was due to externalized conductors.
10 Hauser R et al. Riata ICD lead failure: Results of the manufacturer s analysis of returned leads. JACC. 2012;59(13): E584. Available at: Hauser RG, et al. Riata ICD lead failure: results of the manufacturer's analysis of returned leads. JACC ( 2012 ) vol. 59 issue 13 ( Abstract Supplement ) Saltzman H et al. Conductor exteriorization in the Riata lead experience in a major extraction center. JACC. 2012;59(13): E598. Available at: Hodkinson E et al. Follow-Up Riata Screening in Northern Ireland. JACC ( 2012 ) vol. 59 issue 13 (Abstract Supplement) Hodkinson E, Kodoth V, Ashfield K, et al. FOLLOW-UP RIATA SCREENING IN NORTHERN IRELAND. JACC. 2012;59(13): E585. Available at: Fazal I et al. Incidence of Riata Defibrillator Lead Failure Higher than Previously Reported. Europace 2012; 14(1). Abstract 96P.63. Hauser R, et al. Performance of Riata ICD leads: results from an independent multicenter study. European Heart Journal SUPPL. 1 (539) Abstract Jordaens L et al. Analysis of the Riata 1580, 1581 and 1582 Leads. Europace 2012; 14(1). Abstract 96P.59. Theuns D et al. Impact of fluoroscopic screening on failure rates of the Riata highvoltage implantable defibrillator lead. European Heart Journal SUPPL. 1 (540) Abstract ±18.6 mo MAUDE database. Lead: 105 returned Riata and Riata ST leads Time from implant to extraction: 5 to 108 mos 239 days additional from 1st screening Mean: 52.7±26.2 Riata: 4.3 ± 2.6 Riata ST: 3.3 ± 1.7 Mean: 1705 ± 828 days Median: 4.9 Extraction records from 2009 to Leads: 23 silicone based Riata. 1st screening: 165 leads in Dec nd screening: leads screened = 139 leads, centers = insulation defects (2.11/lead) were found, including 143 inside-out insulation defects (1.36/lead), 34 outside-in defects (0.32/lead), 36 defects caused by the ICD can (0.34/lead), and 9 unspecified defects. Of the 143 inside-out insulation defects, 93 (65.0%) were distal to the proximal shocking coil and 33 (31%) had exposed conductor cables. The ETFE high voltage cable insulation was abraded in 22 of 43 (51.2%) leads reported. Clinical signs of failure included: noise/oversensing (45/105; 42.8%); impedance changes (23/105; 21.9%); high threshold or loss of capture (11/105; 10.4%); and other (26/105; 24.7%) including 7 externalized cables. 9/23 patients had conductor exteriorization (CE) or electrical malfunction (EM). 7 had macroscopic CE. Of the 7 pts with CE, 4 had EM. Of the 6 pts with EM, 4 had CE. Most CE occurred just proximal to a high energy coil. Of the 7 pts with CE, 5 had fluoroscopic evidence of CE prior to extraction; 2 had CE found during extraction. Of the 6 pts with EM, 2 had reduced shock impedance, and 4 had noise sensing. From first screening: 25 leads were positive for insulation breach with conductor separation. From second screening: 26 (19%) were classified as positive for externalized conductors, 3 (2%) borderline and 110 (79%) negative. Overall, lead failure incidence of 2.6%/year and a prevalence of 19%. Riata (N = 69), centers = 1 The Riata lead failure rate was 10.4% (2.4% per year). Leads: Riata (N = 773), Riata ST (N = 287), Quattro (N = 1,668 ), centers = 7 62 out of 1060 (5.8%) of Riata and Riata ST leads failed, including 45 electrical malfunctions (7 with externalized conductors) and 17 normally functioning leads with externalized conductors. Leads = 374 Riata 1580, 1581, 1582 series had a 13.6% failure rate at 7. Leads: Riata (N = 374), Riata ST (N = 78) Post Riata lead recall, 58/452 (12.8%) of Riata silicone leads (8F: N = 374, 7F: N = 78) evaluated by fluoroscopy had externalized conductors. The cumulative failure rate was 6.7% at 5 and 39.7% at 8.
11 Abdelhadi R et al. Independent Multicenter Study of Riata and Riata ST ICD Leads. Heart Rhythm LBCT Abstract SP09 Abdelhadi RH, Saba SF, Ellis CR, et al. Independent multicenter study of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm. 2013;10(3): Cohen T et al. The Pacemaker and Defibrillator Lead Survival and Malfunctions Study: Which Core Lead Design Elements Influence Leads Failure? Heart Rhythm 2012;9(5): S13. AB Corbisiero R et al. Incidence of Externalized Conductors in ICD Leads Using PA and Lateral Chest X-Ray Imaging. Heart Rhythm 2012;9(5): S236. PO3-44. Johansen J et al. Defibrillator Lead Diameter as a Predictor of Lead Survival Time. Heart Rhythm 2012;9(5): S60. AB Johansen J et al. Poor Survival of Defibrillator Leads with Small Diameter. Europace 2012; 14(1). Abstract 96P.58. Noad R et al. Riata lead extraction a single center experience. Heart Rhythm 2012;9:S60. AB Rordorf R et al. Failure of Implantable Cardioverter Defibrillator Leads: Is It a Matter of Lead Size? Heart Rhythm 2012;9(5): S60. AB Rordorf R, Poggio L, Savastano S, et al. Failure of Implantable Cardioverter Defibrillator Leads: Is It a Matter of Lead Size?. Heart Rhythm 2013;10(2): Rordorf R et al. Incidence of ICD lead fracture: comparison of small vs standard-diameter leads implanted in a single center. European Heart Journal SUPPL. 1 (539) Abstract Mean: Riata 8F: 4.2±2.4, Riata ST 7F: 3.3±1.7 Longest: 15, SJM ~8 Leads: Riata (N = 774), Riata ST (N = 307), Quattro (N = 1,668 ). Centers = 7. Leads (N = 2,967) 531 BSX, 840 SJM (85% Riata), 1596 MDT (52% Fidelis). Centers = 1. N/A Leads: Riata (N = 122), Riata ST (N = 191), Durata (N=76), centers = 1 Longest: SJM leads with advisory ~7, SJM leads without advisory ~3.5 Danish ICD Registry. 4 groups: 9+F (N = 2911), SJM 7 and 8F on advisory (N = 310), SJM 7F and 8F not on advisory (N = 458), Fidelis 7F (N = 572), centers = 5 N/A Extracted leads = 26, centers = 1 Median: 33 Leads: Fidelis (N = 190), Riata ST (N = 182), Optim (N=99), standard-size leads (N = 419). Center = 1 Riata 8F leads had a statistically lower survival compared to Sprint Quattro leads (Riata all-cause failure rate: 1.93% per pt yr; Quattro: 0.43% per pt yr). Riata ST 7F leads had similar survival compared to Sprint Quattro leads (Riata ST all cause failure rate: 0.5% per pt yr vs. Quattro: 0.43% per pt yr). 10% of 1081 leads were examined for the presence of externalized conductors and externalized conductors were observed in 25% of examined leads. BSX vs MDT [Hazard ratio (HR) = 0.36 (95% CI: )]; SJM vs MDT [HR = 0.47 ( )]; BSX vs SJM [HR = 0.54 ( )]. Externalized conductors were observed in 6 leads (5 Riata, 1 Riata ST, 0 Durata). The mean time to externalized conductors was 3.86, up to 5.4. One lead with an EC had decreased shock impedance 1.5 after externalized conductors noted. All other leads are functioning normally 1.61 post observation of externalized conductors. All groups < 9F had lower survival compared to 9+F. 7F and 8F leads had lower survival than 9+F leads. 12 out of 26 extracted leads had insulation breach. Out of 12 leads with insulation breach, 10 were Riata 8F leads and 2 were Riata ST 7F leads. Comparable extraction of Riata leads with insulation breach can be achieved with comparable levels of success and expected outcomes to those without insulation breach. The overall fracture rate was 6.3% at a median follow-up of 33. The rate of fracture was: 15.7% for Fidelis, 7.6% for Riata leads, and 2.6% for standard size leads. No cases of lead failure were recorded in the Optim group. Small-diameter (hazard ratio[hr]5.03, , P o.001), Sprint Fidelis (HR 6.3, , P<0.001), or Riata/RiataST (HR4.5, , P<0.001) leads and age < 60 (HR2.3, , P<0.005) were found to independently increase the risk of lead failure.
12 Saltzman H et al. Conductor Exteriorization in the Riata Leads Experience in a Major Extraction Center. JACC ( 2012 ) vol. 59 issue 13 ( Abstract Supplement ) range: 5 to 108 leads extracted = 23 silicone Riata, centers = 1 Externalized conductors were observed in 7 extracted leads: 4 showed no electrical malfunctions. Externalized conductors had no impact on the extraction process. Saltzman HE, Subzposh F, Saari C, et al. The Riata ICD Lead: Extraction Experience For Conductor Exteriorization and Electrical Malfunction. Heart Rhythm. 2012;9(5): S69. AB31-03 See V et al. Variable Pattern of Lead Defects in Riata Family ICD Leads. Heart Rhythm. 2012;9(5): S454. PO Steinberg C et al. High Incidence of Riata Lead Breaches A Single Center Experience. Heart Rhythm. 2012;9(5): S60. AB Wright J et al. Long Term Outcomes of ICD Leads: A Difference in Failure Mechanisms. Heart Rhythm 2012;9(5): S297. PO Zhu D et al. High Incidence of Externalized Conductors in SJM Riata Leads: Results of Fluoroscopic Surveillance From A Single Center in US. Heart Rhythm. 2012;9(5):S445. PO Mean: 38.4 ± 28.7 Mean: 6.6 for abnormal leads vs 5.7 for normal leads Mean: 57 ± 28 Mean: Riata 8F: 6.4 ± 0.7, Riata ST 7F: 4.8 ± 0.5 Leads = 105, centers = 1 Leads = 106 Riata, centers = 1 Leads: 432 Riata/Riatai/Riata ST (N=432), Endotak (N = 326), centers = 1 Leads: Riata (N = 10), Riata ST (N = 12), centers = 1 4 leads (3.7%) had evidence of compromise requiring invasive management (extraction or lead implant). Insulation breach resulting in inappropriate therapy was observed in 2 leads. Externalized conductors were observed in one lead on fluoro without any electrical issues. Time from implant longer in lead defect group (55.6 +/ 17.8 vs /- 28.7, p = NS) PA and lateral chest x-ray showed 21.7% leads with externalized conductors. Abnormal CXR was more frequent with 8F leads compared to 7F leads (28% vs. 7%). 6.2% leads failed during 57 +/- 28. Out of 22 leads screened by fluoro, externalized conductors were detected in 5 Riata leads, and no externalized conductors were detected in Riata ST leads. No significant electrical abnormalities were observed in any leads with externalized conductors. Schmutz M et al. Prevalence of asymptomatic and electrically undetectable intracardiac inside-out abrasion in silicon-coated Riata and Riata ST implantable cardioverter defibrillator leads. Int J Cardiol. 2013;167(1): Available at: Mean: 71±18 Leads: Riata and Riata ST (N=52) 1570 n=7, 1580 n=30, 1582 n=1, 7000 n=6, and 7002 n=8. Center = 1 At a mean time of 71±18 since implantation, intracardiac inside-out abrasion was confirmed by fluoroscopy in 6 patients (out of 52, 11.5%). Mean time from lead implantation to detection of intracardiac inside-out abrasion was 79±14. In all patients with an intracardiac inside-out abrasion, ICD interrogation showed normal and stable electrical parameters. Retrospectively, in 4 of these 6 patients, a coronary angiography performed 25±18 before diagnosis of intracardiac inside-out abrasion already showed the defect. 2 of these 4 patients experienced adequate antitachycardia pacing and ICD-shocks.
13 Kodoth V et al. Riata lead failure; A report from Northern Ireland Riata lead screening programme. European Heart Journal ( 2011 ) 32 ( Abstract Supplement ), 310. Abstract #1838. Kodoth VN, Hodkinson EC, Noad RL, et al. Fluoroscopic and Electrical Assessment of a Series of Defibrillation Leads: Prevalence of Externalized Conductors. Pacing and Clin Electrophysiol. 2012;35: Available at: doi: /pace Epub 2012 Oct ± 1.43 Patients = 212. Leads screened = 165 (five were of model 1570, one of 1571, four of 1572, 13 of 1580, 55 of 1582, 46 of 7000, 31 of 7002, six of 7040, two of 7042, and two of 7022). Centers = 1 After fluoroscopy screening, 15% of leads were classified as positive for externalized conductors.
PUBLICATION SUMMARY PERTAINING TO ABBOTT RIATA LEADS (WITH >100 PATIENTS OR RIATA LEADS UNLESS NOTED)
Abbott 15900 Valley View Court Sylmar, CA 91342 USA Main 818 362 6822 Fax 818 364 5814 PUBLICATION SUMMARY PERTAINING TO ABBOTT RIATA LEADS (WITH >100 PATIENTS OR RIATA LEADS UNLESS NOTED) 2016 2017 Publications
More informationBench testing: ETFE-coated conductors
St. Jude Medical Implantable Electronic Systems 15900 Valley View Court Sylmar, CA 91342 USA Main 818 362 6822 Fax 818 364 5814 Riata Publications Citation Fischer A, Klehn R. Contribution of ethylenetetrafluoroethylene
More informationRiata lead extraction- a single centre experience
Riata lead extraction- a single centre experience Rebecca L Noad, Keith W Morrice, Vivek N Kodoth, Carol M Wilson, Michael JD Roberts. Royal Victoria Hospital, Belfast, United Kingdom Background of previous
More informationRiata Lead Summit Jan 20, SJM Perspective Dr. Mark Carlson
Riata Lead Summit Jan 20, 2012 SJM Perspective Dr. Mark Carlson 1 1 Presentation Outline Background, Characterization of Externalized Conductors Modeling and Testing Diagnostics and Therapeutics Recommendations
More informationThe Riata Implantable Cardioverter Defibrillator Lead: Extraction Experience for Conductor Exteriorization and Electrical Malfunction
The Riata Implantable Cardioverter Defibrillator Lead: Extraction Experience for Conductor Exteriorization and Electrical Malfunction Heath E. Saltzman, MD, Faiz Subzposh, MD, Christine Saari, CRNP, S.
More informationFluoroscopic Grading Scale and Correlation to Lead Extraction in Failed St. Jude Medical Riata Family ICD Leads
Fluoroscopic Grading Scale and Correlation to Lead Extraction in Failed St. Jude Medical Riata Family ICD Leads Sunthosh V Parvathaneni MD 1, Christopher R Ellis MD 1, Jason A Rytlewski MD 1, and Jeffrey
More informationPatient Safety: the optimal lead body design
Patient Safety: the optimal lead body design E. Soldati U.O. Malattie Cardiovascolari II Azienda Ospedaliero Universitaria Pisana Advances in Cardiac Arrhythmias Torino, 25-27 Ottobre 2012 Lead Malfunction
More informationRiata implantable cardioverter-defibrillator lead failure: Analysis of explanted leads with a unique insulation defect
Riata implantable cardioverter-defibrillator lead failure: Analysis of explanted leads with a unique insulation defect Robert G. Hauser, MD, FHRS, Deepa McGriff, BS, Linda Kallinen Retel, BS, FHRS From
More informationICD leads survival and troubles in the last 10 years
XVI Symposium on Progress in Clinical Pacing, Rome, Italy - Dec 2 to 7, 2014 ICD leads survival and troubles in the last 10 years Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial
More informationRiata Lead Extraction. Thomas D. Callahan, MD, FACC, FHRS
Riata Lead Extraction Thomas D. Callahan, MD, FACC, FHRS Outline Riata lead history Lead design Lead Failure Extraction outcomes Techniques Special considerations Riata Lead Background 8F introduced in
More informationDeaths caused by the failure of Riata and Riata ST implantable cardioverter-defibrillator leads
Deaths caused by the failure of Riata and Riata ST implantable cardioverter-defibrillator leads Robert G. Hauser, MD, FHRS, Raed Abdelhadi, MD, Deepa McGriff, BS, Linda Kallinen Retel, BS, FHRS From the
More informationFluoroscopic investigation of Riata transvenous defibrillator leads
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 1, 57 67 DOI: 10.5603/CJ.a2014.0039 Copyright 2015 Via Medica ISSN 1897 5593 Fluoroscopic investigation of Riata transvenous defibrillator leads Gurjit
More informationComplications of Lead Extraction: Prevention and treatment. Maria Grazia Bongiorni, MD, FESC
Complications of Lead Extraction: Prevention and treatment Maria Grazia Bongiorni, MD, FESC Director of Cardiovascular Division University Hospital of Pisa (Italy) ourtesy of Dr Eivind Platou Potential
More informationLeadless Pacing. Osama Diab Assistant Prof. of Cardiology Ain Shams University Egypt
Leadless Pacing Osama Diab Assistant Prof. of Cardiology Ain Shams University Egypt The weakest link in Pacemaker system the lead. The more the leads the more the complications Dislodgement Fracture Insulation
More informationPublication Summary pertaining to St. Jude Medical Durata Leads (with >100 patients and Durata leads unless noted)
St. Jude Medical 15900 Valley View Court Main 818 362 6822 Fax 818 364 5814 Sylmar, CA 91342 USA Publication Summary pertaining to St. Jude Medical Durata Leads (with >100 patients and Durata leads unless
More informationLead Selection and Subcutaneous ICD Considerations. The Future of CIEDs
Lead Selection and Subcutaneous ICD Considerations The Future of CIEDs February, 2013 Steven P. Kutalek, MD Director, Cardiac Electrophysiology Drexel University College of Medicine New Technologies 2012
More informationOutcomes of Defibrillator Lead Implants Performed by High Volume Operators vs. Low Volume Operators:
Outcomes of Defibrillator Lead Implants Performed by High Volume Operators vs. Low Volume Operators: Results from the Pacemaker and Implantable Defibrillator Leads Survival Study ( PAIDLESS ) Partially
More informationthat physicians image Riata and Riata ST leads implanted in patients to assess for externalization or other visible insulation abnormalities.
St. Jude Medical Cardiac Rhythm Management Division 15900 Valley View Court Sylmar, CA 91342-3577 USA Tel 818 362 6822 800 423 5611 www.sjm.com Mark Carlson, MD, MA Chief Medical Officer and Sr. VP Clinical
More informationContinuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
More informationCIEDs Infection: Lead Extraction, First or Last option?
CIEDs Infection: Lead Extraction, First or Last option? More CRM Systems & Leads 600,000 new devices annually 1.2 million new leads annually Sources: 1) Medtronic CRDM Product Performance Report, Jan 2009.
More informationLead Extraction: Challenges in our area
Lead Extraction: Challenges in our area More CRM Systems & Leads 600,000 new devices annually 1.2 million new leads annually Sources: 1) Medtronic CRDM Product Performance Report, Jan 2009. 2) Boston Scientific
More informationThe reliability of an implantable cardioverter-defibrillator. Original Article
1170 Circ Arrhythm Electrophysiol December 2013 1561, 1570, 1571, 1572, 1580, 1581, 1582, 1590, 1591, 1592, 1940, 7000, 7001, 7002, 7010, 7020, 7021, 7022, 7040, 7041, 7042, 7052, 7070, 7071, 7120, 7121,
More informationUpdate on Device Innovation (S-ICD, Wearable, Leadless)
Update on Device Innovation (S-ICD, Wearable, Leadless) C. W. Israel Dept. of Medicine - Cardiology Evangelical Hospital Bielefeld J. W. Goethe University Frankfurt Carsten.Israel@em.uni-frankfurt.de Conflicts
More informationAutomatic Identification of Implantable Cardioverter-Defibrillator Lead Problems Using Intracardiac Electrograms
Automatic Identification of Implantable Cardioverter-Defibrillator Lead Problems Using Intracardiac Electrograms BD Gunderson, AS Patel, CA Bounds Medtronic, Inc., Minneapolis, USA Abstract Implantable
More informationHow to treat Cardiac Resynchronization Therapy complications? C. Leclercq Departement of Cardiology Centre Cardio-Pneumologique Rennes, France
How to treat Cardiac Resynchronization Therapy complications? C. Leclercq Departement of Cardiology Centre Cardio-Pneumologique Rennes, France Presenter Disclosure Information Christophe Leclercq, MD,
More informationSingle- versus Dual-Coil ICD Leads: Does it Matter?
Single- versus Dual-Coil ICD Leads: Does it Matter? C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Conflict of Interest Biotronik Boston-Scientific
More informationThe reliability of an implantable cardioverter-defibrillator. Original Article
Original Article Performance of Lead Integrity Alert to Assist in the Clinical Diagnosis of Implantable Cardioverter Defibrillator Lead Failures Analysis of Different Implantable Cardioverter Defibrillator
More informationDevice Interrogation- Pacemakers, ICD and Loop Recorders. Dulce Obias-Manno, RN, MHSA, CCDS,CEPS, FHRS Device Clinic Coordinator, MHVI
Device Interrogation- Pacemakers, ICD and Loop Recorders Dulce Obias-Manno, RN, MHSA, CCDS,CEPS, FHRS Device Clinic Coordinator, MHVI Disclosures Consultant: Medtronic Speaker s Bureau: St. Jude Medical
More informationPediatric pacemakers & ICDs:
Pediatric pacemakers & ICDs: perioperative management Manchula Navaratnam Clinical Assistant Professor LPCH, Stanford SPA 2016 Conflict of interest: none Objectives Indications in pediatrics Components
More informationThe Incidence of Riata Defibrillator Lead Failure: a Single-Center Experience
ORIGINAL ARTICLE Cardiovascular Disorders https://doi.org/10.3346/jkms.2017.32.10.1610 J Korean Med Sci 2017; 32: 1610-1615 The Incidence of Riata Defibrillator Lead Failure: a Single-Center Experience
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationOHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices
OHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices Ontario Health Technology Advisory Committee January 2012 Issue Background The Ontario
More informationImplantable cardioverter defibrillator, Inappropriate shock, Lead failure
Inappropriate Discharges of Intravenous Implantable Cardioverter Defibrillators Owing to Lead Failure Takashi WASHIZUKA, 1 MD, Masaomi CHINUSHI, 1 MD, Ryu KAZAMA, 1 MD, Takashi HIRONO, 1 MD, Hiroshi WATANABE,
More informationHow Wireless Remote Monitoring Improves Clinical Benefits;
How Wireless Remote Monitoring Improves Clinical Benefits; A CLINICAL CASE STUDY Suneet Mittal, M.D., The Arrhythmia Institute at Valley Hospital, Ridgewood, NJ; New York, New York; E. Martin Kloosterman,
More informationCARDIAC DEVICE MR-CONDITIONAL PRODUCT SUMMARY CHART
CARDIAC DEVICE MR-CONDITIONAL PRODUCT SUMMARY CHART December 2015 This chart encompasses all Medtronic cardiac devices FDA-Approved as MR Conditional and included in the MRI SureScan portfolio. If a device
More informationNew generations pacemakers and ICDs: an update
Advances in Cardiac Arrhythmias and Great Innovations in Cardiology XXVII Giornate Cardiologiche Torinesi New generations pacemakers and ICDs: an update Prof. Fiorenzo Gaita, MD Division of Cardiology
More informationINNOVATIONS IN DEVICE THERAPY:
INNOVATIONS IN DEVICE THERAPY: Subcutaneous ICDs, Leadless Pacemakers, CRT Indications David J Wilber MD Loyola University Medical Center Disclosures: ACC Foundation: Consultant; Biosense / Webster: Consultant,
More informationSubcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death A subcutaneous
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationInappropriate electrical shocks: Tackling the beast
ESC Paris 2011 Inappropriate electrical shocks: Tackling the beast Gerhard Hindricks University of Leipzig Heart Center Dept. of Electrophysiology ESC Paris 2011 Inappropriate electrical shocks: Tackling
More informationEBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA
Over 200,000 patients worldwide are estimated to receive a CRT device each year. However, limitations prevent some patients from benefiting. CHALLENGING PROCEDURE 5% implanted patients fail to have coronary
More informationTop 5 Things to Know about Pacemakers and ICD s. Jeffrey S. Osborn, M.D., C.C.D.S. March 4, 2017.
Top 5 Things to Know about Pacemakers and ICD s Jeffrey S. Osborn, M.D., C.C.D.S. March 4, 2017. Top 5 Things 1. Remote Monitoring leads to better care and outcomes. 2. MRI s CAN be done on device patients.
More informationSupplemental Material
Supplemental Material 1 Table S1. Codes for Patient Selection Cohort Codes Primary PM CPT: 33206 or 33207 or 33208 (without 33225) ICD-9 proc: 37.81, 37.82, 37.83 Primary ICD Replacement PM Replacement
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationCRM PRODUCT PERFORMANCE REPORT
CRM PRODUCT PERFORMANCE REPORT Important Patient Management Information for Physicians CRM Product Performance Report is now available on www.medtronicconnect.com Medtronic Mission: To Strive Without Reserve
More informationDevice Implantation: Long-Term Commitments. Fayez Bokhari, MD, FRCPC Director of Cardiology Military Hospital, Jeddah
Device Implantation: Long-Term Commitments Fayez Bokhari, MD, FRCPC Director of Cardiology Military Hospital, Jeddah Who should Implant ICD? 1. Electrophysiologist 2. Surgeons 3. General Cardiologist with
More informationLeadless pacemakers and subcutaneous ICD s: will we use them for most of our patients? K.-H. Kuck Asklepios Klinik St. Georg Hamburg, Germany
Leadless pacemakers and subcutaneous ICD s: will we use them for most of our patients? K.-H. Kuck Asklepios Klinik St. Georg Hamburg, Germany Disclosure Statement Research Grants Consultant / Advisory
More informationJohn H. Ip, M.D FACC Associate Professor of Medicine Michigan State University Medical Director, EP Service
ICD Trouble shooting: Case study John H. Ip, M.D FACC Associate Professor of Medicine Michigan State University Medical Director, EP Service Bullet proof evidence: ICD does prevent sudden death Disclosures
More informationG Lin, R F Rea, S C Hammill, D L Hayes, P A Brady
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA Correspondence to: Dr Peter A Brady, MD, FRCP, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA; brady.peter@mayo.edu Accepted
More informationRemote monotoring of cardiac rhythm devices: present and future Pacemaker and ICD
Remote monotoring of cardiac rhythm devices: present and future Pacemaker and ICD Philippe Mabo University Hospital, Rennes, France ESC congress, Paris 30 August 2011 U642 Disclosures Biotronik: research
More informationTeaching Rounds in Cardiac Electrophysiology
Teaching Rounds in Cardiac Electrophysiology Sustained Multiple Railroad Tracks on Implantable Cardiac Defibrillator Interval Plots Mechanisms and Management Alex Y. Tan, MD; Kenneth A. Ellenbogen, MD;
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationCardiac Rhythm Management Division Product Performance Report April 2011
Cardiac Rhythm Management Division Product Performance Report April April Letter from St. Jude Medical As a world leader in the development of state-of-the-art technology for cardiac rhythm management
More informationIn 2007, Medtronic recalled the Sprint Fidelis implantable
Trends in Fidelis Lead Survival Transition From an Exponential to Linear Pattern of Lead Failure Over Time Jim W. Cheung, MD; Aviva Tobin-Hess, BA; Apoor Patel, MD; David J. Slotwiner, MD; Bruce G. Goldner,
More informationAalborg Universitet. The St. Jude Medical Riata defibrillator lead advisory Moesgaard, Jacob
Aalborg Universitet The St. Jude Medical Riata defibrillator lead advisory Moesgaard, Jacob DOI (link to publication from Publisher): 10.5278/vbn.phd.med.00025 Publication date: 2015 Document Version Publisher's
More informationICD Diagnostics: Making the most of it
ICD Basics and Beyond ICD Diagnostics: Making the most of it Dulce Obias-Manno RN, BSN, MHSA, FHRS, CCDS, CEPS Cardiac Arrhythmia Center, Device Clinic Washington Hospital Center, Washington DC Objectives
More informationSUPPLEMENTAL MATERIAL: ICD Leads: Design, Diagnostics, and. Management
SUPPLEMENTAL MATERIAL: ICD Leads: Design, Diagnostics, and Management Charles Swerdlow MD* and Kenneth A. Ellenbogen, MD * Cedars Sinai Heart Institute and David Geffen School of Medicine at UCLA, Los
More informationThe transvenous defibrillation lead was a critical technological
Arrhythmia Management Devices Implantable Cardioverter-Defibrillator Leads Design, Diagnostics, and Management Charles D. Swerdlow, MD; Kenneth A. Ellenbogen, MD The transvenous defibrillation lead was
More informationProduct Performance Report
Product Performance Report Cardiac Rhythm Management October 9 October 9 Letter from St. Jude Medical As a world leader in the development of state-of-the-art technology for cardiac rhythm management
More informationMRI-Ready Systems Manual. MRI Procedure Information for the St. Jude Medical MR Conditional System
MRI-Ready Systems Manual MRI Procedure Information for the St. Jude Medical MR Conditional System CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. WARNING: This
More informationInappropriate ICD Discharge Related to Electrical Muscle Stimulation in Chiropractic Therapy: A Case Report
Cardiol Ther (2017) 6:139 143 DOI 10.1007/s40119-017-0086-6 CASE REPORT Inappropriate ICD Discharge Related to Electrical Muscle Stimulation in Chiropractic Therapy: A Case Report Abhishek Shenoy. Abhishek
More informationProduct Performance Report
Product Performance Report Cardiac Rhythm Management May May Letter from St. Jude Medical As a world leader in the development of state-of-the-art technology for cardiac rhythm management devices, St.
More informationEnTrust D154VRC Single Chamber ICD 35J delivered 8 seconds BOL, 11.8 seconds ERI 10.7 years**** 35cc, 68g Programmable Active Can
EnTrust D154ATG Dual Chamber ICD 35J delivered 8 seconds BOL, 11 seconds ERI 7.7 years** 35cc***, 68g Programmable Active Can EnTrust D154VRC Single Chamber ICD 35J delivered 8 seconds BOL, 11.8 seconds
More informationIntegration of diagnostic device information to improve patient management
Integration of diagnostic device information to improve patient management Haran Burri Associate Professor Cardiology Service University Hospital of Geneva Disclosures Biotronik: fellowship support, speaker
More informationMRI imaging for patients with cardiac implantable electronic devices (CIEDs)
MRI imaging for patients with cardiac implantable electronic devices (CIEDs) 13 th annual International Winter Arrhythmia School Collingwood, Ontario, Canada February 6, 2016 Andrew C.T. Ha, MD, MSc, FRCPC
More informationSubcutaneous ICD Emerging Role of Sudden Cardiac Death Prevention
Subcutaneous ICD Emerging Role of Sudden Cardiac Death Prevention Dr Ngai-Yin Chan, MBBS, FRCP(Lond), FRCP(Edin), FRCP(Glasg), FACC, FHRS, Consultant Physician, Department of Medicine & Geriatrics, Princess
More informationMake the Connection A clinical compendium on the relationship between AF, stroke, and early intervention
Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention Data that date back to the 1970 s have illustrated the strong relationship between atrial fibrillation
More informationICD: Basics, Programming and Trouble-shooting
ICD: Basics, Programming and Trouble-shooting Amir AbdelWahab, MD Electrophysiology and Pacing Service Cardiology Department Cairo University Feb 2013 Evolution of ICD Technology ICD Evolution Indications
More informationAdvanced ICD Concepts
1 4 2 5 7 3 6 8 Advanced ICD Concepts This presentation is provided with the understanding that the slide content must not be altered in any manner as the content is subject to FDA regulations. This presentation
More informationINTERPRETING THE ECG IN PATIENTS WITH PACEMAKERS
INTERPRETING THE ECG IN PATIENTS WITH PACEMAKERS BEFORE INTERPRETING THE ECG: Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS. Cardiology San Francisco General Hospital UCSF Disclosures: None 1 2 QUESTIONS
More informationDual-Chamber Implantable Cardioverter-Defibrillator
February 1998 9 Dual-Chamber Implantable Cardioverter-Defibrillator A.SH. REVISHVILI A.N. Bakoulev Research Center for Cardiovascular Surgery, Russian Academy of Medical Sciences, Moscow, Russia Summary
More informationActive Fixation Models: 7740, 7741 and 7742 Passive Fixation Models: 7731, 7732, 7735 and 7736
The INGEVITY MRI pacing leads are 6F (2.0 mm) steroid-eluting, endocardial pace / sense leads designed for permanent implantation for either atrial or ventricular applications. INGEVITY MRI is the only
More informationMRI and CIEDs. Disclosures
Date Clinical Title MRI and CIEDs C. p. Lao Raul Weiss MD, FAHA, FACC, FHRS and CCDS Director, Electrophysiology Fellowship Program Professor of Medicine The Ohio State University Wexner Medical Center
More information12 YEARS PROVEN PERFORMANCE. Sprint Quattro Defibrillation Leads
12 YEARS PROVEN PERFORMANCE Sprint Quattro Defibrillation Leads PROVEN PERFORMANCE. PROVEN RELIABLE. We made intentional choices and took proactive steps from lead design to active product monitoring to
More informationPrevention of Sudden Death in ARVC
ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück
More informationDiagnostic capabilities of the implantable therapeutic systems
Cardiac pacing 2012 and beyound Monday August 27, 2012 Diagnostic capabilities of the implantable therapeutic systems Pekka Raatikainen Heart Center Co. Tampere University Hospital and University of Tampere
More informationSubcutaneous implantable cardioverter-defibrillator (S-ICD)
NEW DRUGS AND TECHNOLOGIES IN CARDIOLOGY Cardiology Journal 2011, Vol. 18, No. 3, pp. 326 331 Copyright 2011 Via Medica ISSN 1897 5593 Subcutaneous implantable cardioverter-defibrillator (S-ICD) S. Suave
More informationInteractive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators
22 March 2002 Interactive Simulator for Evaluating the Detection Algorithms of Implantable Defibrillators F. HINTRINGER, O. PACHINGER Division of Cardiology, Department for Internal Medicine, University
More informationDevice Diagnostics and Stroke Prevention: State of the Art
Device Diagnostics and Stroke Prevention: State of the Art Ass. Prof. Dr. Carsten W. Israel Dept. of Cardiology Evangelical Hospital Bielefeld Germany C.W.Israel@em.uni-frankfurt.de Disclosure of Relationships
More informationAtrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY Turin October 13-15, 2016 Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients Dott.
More informationNOVEL DEVICE TECHNOLOGIES
NOVEL DEVICE TECHNOLOGIES Leadless Pacemakers and Subcutaneous ICDs Do the Benefits Outweigh MRI Incompatibility? Disclosures None Background PPMs and ICDs are very effective therapy for treating bradyarrhythmias
More informationPRODUCT PERFORMANCE REPORT
PRODUCT PERFORMANCE REPORT MAY 215 Contents Contents 1 Sorin CRM commitment to Quality 6 2 Definitions and methods 7 2.1 General definitions......................................... 7 2.2 Malfunctions.............................................
More informationCardiac implantable electronic devices (CIEDs) in children include pacemakers and implantable cardioverter defibrillators (ICDs).
Management of Children with Cardiac Devices Guideline originally developed by Leann Miles, APRN; Lindsey Pumphrey, RN; Srikant Das, MD, and the ANGELS Team. Last reviewed by Lindsey Pumphrey, RN, Srikant
More informationENDURALIFE-powered CRT-D devices for the treatment of heart failure
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Medical technology guidance Assessment report overview ENDURALIFE-powered CRT-D devices for the This assessment report overview has been prepared by the
More informationAdvances in Arrhythmia and Electrophysiology
Advances in Arrhythmia and Electrophysiology Troubleshooting Implanted Cardioverter Defibrillator Sensing Problems I Charles D. Swerdlow, MD; Samuel J. Asirvatham, MD; Kenneth A. Ellenbogen, MD; Paul A.
More informationDefibrillation Testing should be routinely performed at the time of ICD implantation. Jeff Healey MD, MSc, FHRS McMaster University
Defibrillation Testing should be routinely performed at the time of ICD implantation Jeff Healey MD, MSc, FHRS McMaster University Presenter Disclosure Information Jeff S. Healey, MD, MSc, McMaster University,
More informationChapter 14. Risk of Failure of Transvenous Implantable Cardioverter Defibrillator Leads.
Risk of Failure of Transvenous Implantable Cardioverter Defibrillator Leads. C. Jan Willem Borleffs, MD 1 ; Lieselot van Erven, MD, PhD 1 ; Rutger J. van Bommel, MD 1 ; Enno T. van der Velde, PhD 1 ; Ernst
More information12 th International Winter Arrhythmia School Collingwood, Ontario February 7, Dr. Derek Yung. MD, FRCPC
12 th International Winter Arrhythmia School Collingwood, Ontario February 7, 2015 Dr. Derek Yung. MD, FRCPC Presenter: Dr. Derek Yung Relationships with industry: Educational material provided by Biotronik,
More informationMEDTRONIC CARELINK NETWORK FOR PACEMAKERS. Comparison between the Medtronic CareLink Network for Pacemakers and Transtelephonic Monitoring
MEDTRONIC CARELINK NETWORK FOR PACEMAKERS Comparison between the Medtronic CareLink Network for Pacemakers and Transtelephonic Monitoring Transtelephonic Monitoring Transmission What can you determine
More informationClinical Data Summary: Avoid FFS Study
Atrial Pacing Lead with 1.1 mm Tip-to-Ring Spacing Clinical Data Summary: Avoid FFS Study A Multi-center, Randomized, Prospective Clinical Study Designed to Evaluate the 1699T Lead Clinical Data Summary:
More informationCall Medtronic at 1 (800) to verify the patient s current implanted system
MRI SURESCAN SYSTEMS Patient Scanning Process Transvenous Implantable Cardiac Systems PATIENT PRESCREENING SureScan Pacing, Defibrillation, and CRT (CRT-D and CRT-P) Systems Verification Verify that patient
More informationEssentials of Pacemakers and ICD s. Rajesh Banker, MD, MPH
Essentials of Pacemakers and ICD s Rajesh Banker, MD, MPH Pacemakers have 4 basic functions: Stimulate cardiac depolarization Sense intrinsic cardiac function Respond to increased metabolic demand by providing
More informationValidation of defibrillator lead performance registry data: insight from the Danish Pacemaker and ICD Register
Europace (2017) 19, 1187 1192 doi:10.1093/europace/euw226 CLINICAL RESEARCH Leads and lead extraction Validation of defibrillator lead performance registry data: insight from the Danish Pacemaker and ICD
More informationManagement of RT patients with implanted cardiac devices: From recommendation to implementation
Management of RT patients with implanted cardiac devices: From recommendation to implementation Coen Hurkmans Clinical Physicist Catharina Hospital Eindhoven The Netherlands 1/22 Outline CIED relocation.
More informationMEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationImplantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?
Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Helmut Pürerfellner, MD, Assoc. Prof. Saint Elisabeth s Sisters Hospital Academic Teaching Center Linz/Austria
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationTo investigate the safe levels of radiotherapy administered to patients who have an implanted cardiac device.
043 Lauren Evans To investigate the safe levels of radiotherapy administered to patients who have an implanted cardiac device. 4061.40 Summary With an ageing UK population, the number of patients with
More informationHeart Rhythm Society. Welcome to San Francisco! 2/26/2013. WS #5 ICD Introduction 1. Workshop # 9. ICD Registry Program
Welcome to San Francisco! Workshop # 9 ICD Registry Program Thursday March 7, 2013 4:00pm 5:30pm Heart Rhythm Society Presenter Disclosure Information Chairman, ICD Registry Steering Committee The following
More information11 YEARS PROVEN PERFORMANCE. Sprint Quattro Defibrillation Leads
11 YEARS PROVEN PERFORMANCE Sprint Quattro Defibrillation Leads PROVEN PERFORMANCE. PROVEN RELIABLE. We made intentional choices and took proactive steps from lead design to active product monitoring to
More information